Stromal AR Roles in Prostate Hyperplasia and Cancer

基质 AR 在前列腺增生和癌症中的作用

• 批准号: 8830282
• 负责人: CHAWNSHANG CHANG
• 金额: $ 32.06万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8830282
• 关键词: Address; Affect; Aging; Androgen Receptor; Androgens; Animal Model; Animals; Apoptosis; Area; Attention; Benign Prostatic Hypertrophy; Biological Assay; Biological Models; Breeding; Cancer Etiology; Cancerous; Cell Culture Techniques; Cell Line; Cell physiology; Cells; Cessation of life; ChIP-seq; Choristoma; Coculture Techniques; Data; Development; Disease; Disease Progression; Elderly; Elderly man; Endocrine system; Epithelial; Epithelial Cells; Epithelium; Etiology; Fibroblasts; Frequencies; Future; Gene Targeting; Generations; Genetic Recombination; Growth; Homeostasis; Human; Image; Immune; In Vitro; Incidence; Investigation; Knock-out; Knockout Mice; Lead; Lesion by Stage; Malignant Neoplasms; Malignant neoplasm of prostate; Mediating; Mesenchymal; Modeling; Molecular; Mus; PTEN gene; Pathway interactions; Phenotype; Physiological; Play; Prolactin; Prostate; Prostatic Diseases; Prostatic Neoplasms; Prostatic hypertrophy; Publications; Rattus; Receptor Signaling; Recombinants; Reporting; Research; Rodent; Role; SCID Mice; Signal Transduction; Smooth Muscle; Stream; Stromal Cells; Structure; Symptoms; System; Therapeutic; Tissues; Transgenic Mice; Urination; alternative treatment; cancer initiation; carcinogenesis; cell stroma; cell type; implantation; in vivo; in vivo Model; insight; intraepithelial; men; mouse model; nephrogenesis; novel; pre-clinical; probasin; promoter; prostate cancer cell; prostate cancer model; prostate carcinogenesis; public health relevance; receptor function; response; transgenic adenocarcinoma of mouse prostate; tumor progression; urinary

DESCRIPTION (provided by applicant): It has been suggested that normal prostate development, benign prostate hyperplasia (BPH), and prostate cancer development all require androgen/androgen receptor (AR) signaling in human and rodent. There are two types of cells, epithelial and stromal cells, constituting the prostate gland structure and mediating the physiological functions. The expression of AR in both epithelial and stromal cells may play important roles in controlling the homeostasis of prostate growth. Our recent data suggested that double stromal-cre ARKO (d-ARKO) mouse prostates have a profoundly reduced stromal AR function and impact on the homeostasis of prostate epithelial cells. We hypothesize that the AR in the stromal cells could play differential roles in benign prostate hyperplasia (BPH) and carcinogenesis. The reason we would like to compare stromal AR role in the BPH vs. cancer is that it will lead to more insights how stromal AR may differentially contribute to the etiology and progression of these two most commen prostate diseases in elder men. In the prostate field, even though there are available in vitro cell lines or tissue recombinant system to study stromal AR roles in normal prostate development, the kidney capture recombination system is grown in immune deficient mice without proper prostate microenvironment and can be only studied in 4-7 weeks. Therefore there is a lack of long-term in vivo model to investigate stromal AR impact on the BPH and prostate carcinogenesis. To date, there are still no suitable preclinical mouse models to study the stromal AR function. We propose to generate the double cre-ARKO (d-ARKO) for understanding the stromal AR role in development of BPH and carcinogenesis. Three Specific Aims will be pursued. Aim 1. To study the stromal AR role in BPH by crossing stromal d-ARKO mice with prolactin transgenic mice. Aim 2. Generation of mouse models with stromal-fibroblast/smooth muscle selective double-cre AR knockout (d-ARKO) and investigation of prostate tumorigenesis and tumor progression. Aim 3. Studying target gene and molecular mechanisms of stromal AR that could affect the epithelium during development of BPH and the prostate cancer. The accomplishment of the project will help us gain insights on the role of stromal AR in the prostate homeostasis and cancerous transformation and progression, and the results could also lead to developing new alternative treatments for BPH and prostate cancer in the future.

描述（由申请人提供）：已经表明，在人类和啮齿动物中，正常前列腺发育、良性前列腺增生（BPH）和前列腺癌的发生都需要雄激素/雄激素受体（AR）信号传导。 有两种类型的细胞，上皮细胞和基质细胞，构成前列腺结构并介导生理功能。 前列腺上皮细胞和间质细胞中AR的表达可能在控制前列腺生长的稳态中起重要作用。 我们最近的数据表明，双间质-cre ARKO（d-ARKO）小鼠前列腺具有显著降低的间质AR功能，并影响前列腺上皮细胞的稳态。 我们推测基质细胞中的AR可能在良性前列腺增生（BPH）和癌变中发挥不同的作用。 我们想要比较基质AR在BPH与癌症中的作用的原因是，它将导致更多的见解，基质AR如何在老年男性中对这两种最常见的前列腺疾病的病因和进展做出不同的贡献。 在前列腺领域，尽管有可用的体外细胞系或组织重组系统来研究基质AR在正常前列腺发育中的作用，但肾捕获重组系统在没有适当前列腺微环境的免疫缺陷小鼠中生长，并且只能在4-7周内进行研究。 因此，缺乏研究基质AR对BPH和前列腺癌发生的影响的长期体内模型。 迄今为止，仍然没有合适的临床前小鼠模型来研究基质AR功能。 我们建议产生双cre-ARKO（d-ARKO），以了解间质AR在BPH和癌发生发展中的作用。 将实现三个具体目标。 目标1。通过间质d-ARKO小鼠与催乳素转基因小鼠杂交研究间质AR在BPH中的作用。 目标2.用基质成纤维细胞/平滑肌选择性双cre AR敲除（d-ARKO）产生小鼠模型并研究前列腺肿瘤发生和肿瘤进展。 目标3。研究间质AR在BPH和前列腺癌发生发展过程中对上皮细胞影响的靶基因和分子机制。 该项目的完成将有助于我们深入了解基质AR在前列腺稳态和癌症转化和进展中的作用，其结果也可能导致未来开发新的BPH和前列腺癌替代治疗方法。

项目成果

Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression.

• DOI: 10.2337/db12-0135
• 发表时间: 2013-02
• 期刊: Diabetes
• 影响因子: 7.7
• 作者: Yu IC;Lin HY;Liu NC;Sparks JD;Yeh S;Fang LY;Chen L;Chang C
• 通讯作者: Chang C

Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.

• DOI: 10.1016/j.molonc.2014.07.013
• 发表时间: 2015-01
• 期刊: Molecular oncology
• 影响因子: 6.6
• 作者: Hu S;Li L;Yeh S;Cui Y;Li X;Chang HC;Jin J;Chang C
• 通讯作者: Chang C

Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

使用 miR-32-5p 通过改变 miR-32-5p/TR4/HGF/Met 信号传导抑制透明细胞肾细胞癌转移的临床前研究

• DOI: 10.1002/ijc.31289
• 发表时间: 2018-07-01
• 期刊: International journal of cancer
• 影响因子: 6.4
• 作者: Wang M;Sun Y;Xu J;Lu J;Wang K;Yang DR;Yang G;Li G;Chang C
• 通讯作者: Chang C

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.

• DOI: 10.1038/cddis.2013.270
• 发表时间: 2013-08-08
• 期刊: Cell death & disease
• 影响因子: 9

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.

• DOI: 10.1038/s41419-020-02970-4
• 发表时间: 2020-11-02
• 期刊: Cell death & disease
• 影响因子: 9
• 作者: Chou FJ;Lin C;Tian H;Lin W;You B;Lu J;Sahasrabudhe D;Huang CP;Yang V;Yeh S;Niu Y;Chang C
• 通讯作者: Chang C